MacCallum S, Groves M, Brass D, Cunningham J, Sales M, Gelly K, Tauro S
Centre for Oncology and Molecular Medicine, Division of Medical Sciences, University of Dundee, Dundee, Scotland, UK.
J Clin Pathol. 2009 May;62(5):468-70. doi: 10.1136/jcp.2008.061143.
Autoimmune haemolysis or thrombocytopenia can complicate purine nucleoside monotherapy for chronic lymphocytic leukaemia (CLL), but Evans syndrome is rare. This is a report of the occurrence of pancytopenia secondary to a unique combination of red cell aplasia with autoimmune thrombocytopenia and neutropenia in a patient with CLL following treatment with fludarabine and cyclophosphamide. This case is unusual for the simultaneous targeting of three haemopoietic lineages by immune dysfunction following fludarabine and cyclophosphamide, which is a treatment regimen believed to reduce autoimmune haematological toxicity in CLL.
自身免疫性溶血或血小板减少症可能会使慢性淋巴细胞白血病(CLL)的嘌呤核苷单药治疗复杂化,但伊文氏综合征较为罕见。本文报告了1例CLL患者在接受氟达拉滨和环磷酰胺治疗后,出现全血细胞减少症,继发于红细胞再生障碍合并自身免疫性血小板减少症和中性粒细胞减少症的独特组合。该病例不同寻常之处在于,氟达拉滨和环磷酰胺治疗后免疫功能紊乱同时针对三个造血谱系,而该治疗方案据信可降低CLL患者的自身免疫性血液学毒性。